Catalyst Pharmaceutical Partners’ (CPRX) “Buy” Rating Reaffirmed at Roth Capital
Catalyst Pharmaceutical Partners Inc. (NASDAQ:CPRX)‘s stock had its “buy” rating restated by research analysts at Roth Capital in a research note issued to investors on Friday. They currently have a $2.50 price target on the biopharmaceutical company’s stock. Roth Capital’s target price would indicate a potential upside of 85.19% from the company’s previous close.
Other analysts also recently issued reports about the company. Zacks Investment Research raised Catalyst Pharmaceutical Partners from a “hold” rating to a “buy” rating and set a $1.00 target price for the company in a report on Tuesday, June 21st. Piper Jaffray Cos. raised Catalyst Pharmaceutical Partners from a “neutral” rating to an “overweight” rating and set a $4.00 target price for the company in a report on Wednesday, October 5th. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average price target of $3.38.
Catalyst Pharmaceutical Partners (NASDAQ:CPRX) opened at 1.35 on Friday. The stock has a 50 day moving average price of $1.13 and a 200 day moving average price of $0.89. Catalyst Pharmaceutical Partners has a 52-week low of $0.51 and a 52-week high of $3.55. The stock’s market cap is $111.87 million.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/10/17/catalyst-pharmaceutical-partners-cprx-buy-rating-reaffirmed-at-roth-capital.html
Catalyst Pharmaceutical Partners (NASDAQ:CPRX) last posted its earnings results on Tuesday, August 9th. The biopharmaceutical company reported ($0.06) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.08) by $0.02. On average, equities research analysts forecast that Catalyst Pharmaceutical Partners will post ($0.25) EPS for the current year.
A number of institutional investors have recently modified their holdings of CPRX. Royal Bank of Canada bought a new position in shares of Catalyst Pharmaceutical Partners during the second quarter valued at about $117,000. Oxford Asset Management boosted its position in Catalyst Pharmaceutical Partners by 3.5% in the second quarter. Oxford Asset Management now owns 180,721 shares of the biopharmaceutical company’s stock valued at $128,000 after buying an additional 6,140 shares during the last quarter. DRW Securities LLC acquired a new position in Catalyst Pharmaceutical Partners during the second quarter valued at about $168,000. Paloma Partners Management Co acquired a new position in Catalyst Pharmaceutical Partners during the second quarter valued at about $200,000. Finally, Renaissance Technologies LLC acquired a new position in Catalyst Pharmaceutical Partners during the first quarter valued at about $206,000. Hedge funds and other institutional investors own 30.64% of the company’s stock.
About Catalyst Pharmaceutical Partners
Catalyst Pharmaceuticals, Inc, formerly Catalyst Pharmaceutical Partners, Inc, is a development-stage biopharmaceutical company. The Company is focused on developing and commercializing therapies for people with rare debilitating diseases. The Company has three drugs in development: Firdapse, CPP-109 and CPP-115.
Receive News & Ratings for Catalyst Pharmaceutical Partners Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Pharmaceutical Partners Inc. and related companies with MarketBeat.com's FREE daily email newsletter.